Extracorporeal Photochemotherapy for Generalized Deep Morphea

Jason H. Neustadter, MD; Frank Samarin, MD; Kacie R. Carlson, PA-C; Michael Girardi, MD; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

Findings from a comprehensive metabolic profile and complete blood cell count were within reference range, including a normal eosinophil count. An antinuclear antibody test was positive with a titer of 1:320 and a speckled pattern. Findings from an upper endoscopy were unremarkable. Clinical presentation and findings from a punch biopsy specimen from the abdomen were consistent with generalized and deep morphea.

Previous treatments were numerous and included several topical corticosteroids, calcipotriene, and tacrolimus. Oral tetracycline antibiotics were prescribed for 6 years, including doxycycline, once daily, and minocycline, twice daily. Multiple prednisone tapers with a maintenance dose of 5 mg every other day were prescribed over a 2-year period. This was followed by several other unsuccessful therapeutic trials: psoralen–UV-A phototherapy 3 times a week for 7 months; azathioprine, 50 mg twice daily for 6 months; and mycophenolate mofetil for 1 year, up to a maximum oral dose of 6 g/d. Despite these therapeutic trials, the patient continued to experience progression of her disease.

The treatment of generalized deep morphea is challenging, and no single therapy has proven to be very effective or significantly disease modifying.1,2 Numerous treatments, some with potentially hazardous adverse effects, are currently used with only limited success.3

Figure 1. The patient’s abdominal skin prior to treatment. Indurated and bound-down plaques coalesced to involve most of the abdominal skin. These lesions were tender to palpation and pruritic.
Topical and intralesional corticosteroids may be useful for discrete lesions, and newer topical agents such as tacrolimus ointment and imiquimod cream have shown some benefit in open-label trials. Daily antimalarial agents, such as hydroxychloroquine, are prescribed, presumably for their immunomodulating properties. Systemic corticosteroids are used for more advanced disease and have been shown to be beneficial in an open-label study, as has methotrexate with and without pulsed methylprednisolone. Other agents that have been tried include vitamin E, topical and oral calcipotriol, aminobenzoate potassium, phenytoin sodium, penicillin and tetracycline antibiotics, retinoids, interferon gamma, cytotoxic agents, and bosentan (an endothelin receptor antagonist). Most of these therapies have shown mixed results. Partial responses have been reported with broadband UV-A treatment with and without 8-methoxypsoralen, and with high- and low-dose long-wave UV-A1 therapy. Physical therapy is particularly important in deep morphea to prevent joint deformities and skin contractures.

Extracorporeal photochemotherapy is an immunotherapy in which a patient’s peripheral blood leukocytes are isolated, bathed in the photosensitizing compound 8-methoxypsoralen, passed through a thin plastic exposure plate while irradiated with UV-A light, and returned intravenously. Based on our experience using ECP in the treatment of chronic graft-vs-host disease (GVHD), and because the patient had failed all previ-ously attempted treatments, the decision was made to attempt a 4-month trial of ECP.

The patient initially began ECP with a regimen of 2 consecutive treatment days at 2-week intervals. She also began weekly physical therapy sessions. She reported improvement in her symptoms within 1 to 2 months of starting treatment. She first noticed an increased energy level, increased hair growth on her legs, and increased flexibility. She has had a dramatic improvement in her symptoms and has maintained a marked softening of hardened, sclerotic skin on her abdomen and upper and lower extremities, as well as increased ranges of motion in her shoulders. Of note, the plaques on her abdomen have resolved (Figure 2), and the near-circumferential plaques on her thighs have become mild and faded. There was a clear objective response to treatment as evidenced by her improved ranges of motion at the shoulders as measured by her physical therapist (Figure 3). By 4 months after starting ECP, her treatment interval was decreased to every 3 weeks, and then to every 4 weeks 3 months later.

Subjectively, the patient is, in her own words, able to “enjoy life again,” taking on projects like yard work and cooking, which were once not feasible owing to fatigue and decreased mobility. She is currently working her regularly scheduled hours and is no longer awakening at night with pain and discomfort in her skin and joints. We have been attempting to taper her treatments using a protocol based on our experience with chronic GVHD. She is currently being treated on 2 consecutive days every 5 weeks with a taper schedule as follows: 3 treatments at every 6 weeks, then 3 treatments at every 7 weeks, then 3 treatments at every 8 weeks, then, if stable, treatment will be discontinued.

Scleroderma encompasses a spectrum of disorders characterized by thickening of the skin and subcutaneous tissue. The 2 main clinical categories of scleroderma include systemic sclerosis, in which visceral changes are present, and localized scleroderma or morphea, in which lesions are limited to the skin and subcutaneous tissues. Peterson et al7 proposed a morphea classification that is used commonly today and includes the following types of morphea: plaque, generalized, bullous, linear and deep, with several types of morphea each having further subtypes. Deep morphea is present when inflammation and sclerosis are found in the deep dermis, panniculus, fascia, or superficial muscle. Generalized morphea occurs when individual plaques number 4 or more and are larger than 3 cm in diameter, become confluent lesions or multiply, and/or affect more than 2 anatomic sites. The distinction between deep and generalized morphea is not clear, and the patient presented in this case would most accurately be characterized as having both deep morphea (morphea profunda) and generalized morphea.

Deep morphea (morphea profunda) is characterized by plaques that are diffuse, mildly inflamed, hyperpigmented, symmetrical, and somewhat ill defined. The skin feels thickened, taut, and bound down to the underly-
ing fascia and muscle. Plaques are smooth and shiny, but areas of both dermal and subcutaneous atrophy may be present, especially in chronic lesions. The onset of sclerosis is gradual and tends to occur over a period of several months. Flexion contractures of the joints are a relatively frequent finding, as is carpal tunnel syndrome. Arthralgias, arthritis, or myalgias are commonly present, as is the case with our patient.

The onset of generalized morphea is usually insidious, and it can progress to involve widespread areas of the body. Lesions mainly involve the upper trunk, breast, abdomen, and upper thighs; however, the arms, face, neck, and scalp may also be involved. Despite extensive skin involvement, these patients rarely have internal organ involvement, but up to 40% may experience arthralgias.

The cause of morphea is unknown. Fibroblast proliferation and excessive accumulation of extracellular matrix proteins, mainly collagen, is the final common pathway. Transforming growth factor beta, interleukin 1 (IL-1), IL-2, IL-4, IL-6, IL-8, IL-13, and connective tissue growth factor are thought to play important roles in pathogenesis, although the details have not yet been fully elucidated. An autoimmune cause is supported by the presence of autoantibodies. Diagnosis of morphea is based on clinicopathologic correlation. Homogenization of collagen bands is the basic histologic change. Histologic differentiation among the different types of morphea is determined by the depth of inflammation and sclerosis, although there is considerable histologic overlap.

Hypergammaglobulinemia, peripheral eosinophilia, and an increased erythrocyte sedimentation rate can all be seen in patients with morphea. Various circulating autoantibodies can be found in all types of morphea, with most titers correlating with the burden of skin disease. Antinuclear antibodies are found in 46% to 80% of cases, anti-single-stranded DNA antibodies are found in 50% of cases, and antihistone antibodies are found in 47% to 87% of cases. Rheumatoid factor is seen in up to 60% of cases of morphea and in up to 82% of cases of generalized morphea and may predict articular involvement. Antitopoisomerase IIA antibodies are found in up to 76% of patients with morphea and in 83% of those with generalized morphea.

The natural history of disease progression is variable; however, the long-term prognosis of patients with morphea is generally good. Lesions of morphea tend to be self-limited with activity or progression lasting 3 to 5 years, followed by residual pigmented and atrophic changes. Less commonly, reactivation can occur or cases will become generalized, progress for several years, and result in marked deformities.

Extracorporeal photochemotherapy is one of the most successful and broadly applied forms of immunotherapy, used in the treatment of cutaneous T-cell lymphoma, transplant rejection, autoimmune diseases, and GVHD. Extracorporeal photochemotherapy showed beneficial results in a single study in 1 patient with linear morphea, with reduction in plaque number and decreased prominence of remaining plaques. It has also been shown to be effective to varying degrees in the treatment of systemic sclerosis and chronic GVHD, diseases that share many similarities with generalized deep morphea.

After 6 months of treatment, a statistically significant reduction in skin severity scores was observed in 68% of patients receiving ECP compared with 32% of patients prescribed a regimen of D-penicillamine. The efficacy of ECP in systemic sclerosis was further evaluated in a more recent randomized, double-blind, placebo-controlled clinical trial conducted at 16 investigational sites worldwide. A statistically significant improvement in skin scores and joint involvement compared with baseline was observed at 6 months and 12 months among those who received active ECP.

The mechanism by which ECP is of therapeutic benefit in morphea, systemic sclerosis, and chronic GVHD remains unproven. However, because systemic sclerosis, chronic GVHD, and generalized deep morphea share clinical and histologic skin findings, the proposed mechanisms of action of ECP in chronic GVHD and systemic sclerosis might apply to morphea as well. Experimental data from animal autoimmune and transplantation studies suggest that photopheresed cells induce an antigen-specific immune response against pathogenic T-cell populations without affecting general immunocompetence. It has also been shown that a considerable proportion of patients with systemic sclerosis and chronic GVHD have an expanded monoclonal T-cell population both in their peripheral blood and at the sites of tissue damage. These T-cell populations may play an autoreactive, disease-mediating role in morphea, systemic sclerosis, and chronic GVHD and may be the target of an immune response induced by ECP. It has been postulated that the immature dendritic cells shown to be produced by ECP may suppress such unwanted immune effector cells through induction of CD25, CTLA-4 regulatory T cells. Furthermore, at least with respect to patients with chronic GVHD, patients with a dominant peripheral T-cell clone seem to show the highest clinical response to ECP. This has yet to be studied in morphea.

In conclusion, the patient in the case presented herein experienced both a reactivation of disease and an aggressive, progressive clinical course prior to starting ECP. Fortunately, she has benefited profoundly from this treatment. Because ECP is one of the safest treatment options for morphea, with a very low adverse effect profile, it should be further investigated and incorporated in the treatment arsenal for this disease.

Accepted for Publication: February 23, 2008.
Correspondence: Michael Girardi, MD, Department of Dermatology, Yale University School of Medicine, 333 Cedar St, LC1 501, PO Box 208059, New Haven, CT 06520-8059 (Michael.Girardi@yale.edu).

Author Contributions: All of the authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Neustadter and Girardi. Acquisition of data: Neustadter, Carlson, and Girardi. Analysis and interpretation of data: Neustadter, Samarin, and Girardi. Drafting of the manuscript: Neustadter and Samarin. Critical revision of the manu
script for important intellectual content: Neustadter, Carlson, and Girardi. Administrative, technical, and material support: Neustadter, Samarin, Carlson, and Girardi. Study supervision: Girardi.

Financial Disclosure: None reported.

REFERENCES


Clinicians, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Manuscripts should be prepared double-spaced with right margins nonjustified. Pages should be numbered consecutively with the title page separated from the text (see Instructions for Authors [http://archderm.ama-assn.org/misc/ifora.dtl] for information about preparation of the title page). Clinical photographs, photomicrographs, and illustrations must be sharply focused and submitted as separate JPG files with each file numbered with the figure number. Material must be accompanied by the required copyright transfer statement (see authorship form [http://archderm.ama-assn.org/misc/auinst_crit.pdf]). Preliminary inquiries regarding submissions for this feature may be submitted to George J. Hruza, MD (ghruza@aol.com). Manuscripts should be submitted via our online manuscript submission and review system (http://manuscripts.archdermatol.com).